Cipher Pharmaceuticals (TSE:CPH) Share Price Passes Below 50-Day Moving Average of $8.72

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$8.72 and traded as low as C$8.40. Cipher Pharmaceuticals shares last traded at C$8.43, with a volume of 12,318 shares.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus cut Cipher Pharmaceuticals from a “buy” rating to a “hold” rating and increased their price target for the company from C$8.00 to C$9.50 in a report on Monday, May 13th.

Cipher Pharmaceuticals Trading Down 0.4 %

The company has a quick ratio of 2.67, a current ratio of 7.96 and a debt-to-equity ratio of 0.38. The company’s 50-day moving average is C$8.72 and its 200-day moving average is C$7.61. The stock has a market capitalization of C$203.25 million, a price-to-earnings ratio of 6.85 and a beta of 1.05.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings results on Thursday, May 9th. The company reported C$0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C$0.14 by C$0.13. Cipher Pharmaceuticals had a net margin of 102.43% and a return on equity of 29.70%. The business had revenue of C$7.91 million during the quarter, compared to the consensus estimate of C$7.04 million. Research analysts anticipate that Cipher Pharmaceuticals Inc. will post 0.74 earnings per share for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.